Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05021978 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of PRAX-944 in Participants With Essential Tremor
A Phase 2 study, sponsored by Praxis Precision Medicines.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT05021978 is a Phase 2 study that has completed, run by Praxis Precision Medicines. The registered enrollment target is 24 participants.
The verdict
NCT05021978, a Phase 2 study, has completed, sponsored by Praxis Precision Medicines.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a 2-part clinical trial to evaluate the efficacy, safety, and tolerability of 40 and 120 mg oral PRAX-944 compared to placebo in the treatment of adults with essential tremor. Part A is designed to study the dose titration from 20 to 40 mg every morning (QAM) (ie, 2 weeks with 7 days at each dose level). Part B is designed to study the dose titration from 20 to up to 120 mg QAM with at least 14 days of dosing at the highest tolerated dose for each participant. Blood levels of PRAX-944 will also be measured throughout the trial and pharmacokinetics will be evaluated.
Interventions
- DRUG Part A: 20 and 40 mg PRAX-944
- DRUG Part B: 120 mg PRAX-944
- DRUG Part B: 120 mg PRAX-944 and Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-03-03 |
| Est. Completion | 2022-03-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05021978
The ClinicalTrials.gov registry entry for NCT05021978 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Praxis Precision Medicines, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Part A: 20 and 40 mg PRAX-944 is the first listed.
NCT05021978 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05021978 about?
NCT05021978 is a clinical study titled "A Clinical Trial of PRAX-944 in Participants With Essential Tremor". This is a 2-part clinical trial to evaluate the efficacy, safety, and tolerability of 40 and 120 mg oral PRAX-944 compared to placebo in the treatment of adults with essential tremor. Part A is designed to study the dose titration from 20 to 40 mg every morning (QAM) (ie, 2 weeks with 7 days at each...
What is the current status of trial NCT05021978?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2020-03-03. Estimated completion is 2022-03-24.
What interventions are being tested in trial NCT05021978?
The interventions under investigation include: Part A: 20 and 40 mg PRAX-944 (DRUG), Part B: 120 mg PRAX-944 (DRUG), Part B: 120 mg PRAX-944 and Placebo (DRUG).
Who is sponsoring clinical trial NCT05021978?
This trial is sponsored by Praxis Precision Medicines, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.